HK1126429A1 - Stabilized insulin-like growth factor polypeptides - Google Patents
Stabilized insulin-like growth factor polypeptidesInfo
- Publication number
- HK1126429A1 HK1126429A1 HK09105411.1A HK09105411A HK1126429A1 HK 1126429 A1 HK1126429 A1 HK 1126429A1 HK 09105411 A HK09105411 A HK 09105411A HK 1126429 A1 HK1126429 A1 HK 1126429A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- growth factor
- factor polypeptides
- stabilized insulin
- insulin
- stabilized
- Prior art date
Links
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 title 1
- 102000013275 Somatomedins Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81234906P | 2006-06-09 | 2006-06-09 | |
US86224406P | 2006-10-20 | 2006-10-20 | |
US89718707P | 2007-01-24 | 2007-01-24 | |
PCT/US2007/070468 WO2007146689A2 (fr) | 2006-06-09 | 2007-06-06 | Polypeptides du facteur de croissance de type insuline stabilisés |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1126429A1 true HK1126429A1 (en) | 2009-09-04 |
Family
ID=38801859
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK09105411.1A HK1126429A1 (en) | 2006-06-09 | 2009-06-17 | Stabilized insulin-like growth factor polypeptides |
Country Status (33)
Country | Link |
---|---|
US (4) | US8343918B2 (fr) |
EP (2) | EP2032155B1 (fr) |
JP (2) | JP2009539805A (fr) |
KR (1) | KR101459789B1 (fr) |
AR (1) | AR061242A1 (fr) |
AU (2) | AU2007255419A1 (fr) |
BR (2) | BRPI0712052A2 (fr) |
CA (2) | CA2654944C (fr) |
CL (1) | CL2007001614A1 (fr) |
CR (2) | CR10432A (fr) |
CY (1) | CY1116117T1 (fr) |
DK (2) | DK2032155T3 (fr) |
EC (1) | ECSP088949A (fr) |
ES (1) | ES2529261T3 (fr) |
GT (1) | GT200800273A (fr) |
HK (1) | HK1126429A1 (fr) |
HR (1) | HRP20150326T1 (fr) |
IL (1) | IL195156A (fr) |
JO (1) | JO2968B1 (fr) |
MA (1) | MA30503B1 (fr) |
MX (2) | MX2008015726A (fr) |
MY (1) | MY147856A (fr) |
NO (2) | NO20085184L (fr) |
NZ (2) | NZ572708A (fr) |
PE (1) | PE20080715A1 (fr) |
PL (1) | PL2032155T3 (fr) |
PT (1) | PT2032155E (fr) |
RU (1) | RU2477287C2 (fr) |
SI (1) | SI2032155T1 (fr) |
TN (1) | TNSN08509A1 (fr) |
TW (1) | TWI427084B (fr) |
UA (1) | UA97953C2 (fr) |
WO (2) | WO2007141309A2 (fr) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090318355A1 (en) * | 2006-02-15 | 2009-12-24 | Chen Thomas T | Compositions and methods for promoting tissue repair and wound healing |
BRPI0712052A2 (pt) | 2006-06-09 | 2012-01-10 | Novartis Ag | polipeptìdeos de fator de crescimento tipo insulina estabilizados |
AU2009244148B2 (en) * | 2008-05-07 | 2014-10-09 | Biomarin Pharmaceutical Inc. | Lysosomal targeting peptides and uses thereof |
US8753632B2 (en) * | 2008-11-10 | 2014-06-17 | Novartis Ag | Antibodies to modified human IGF-1/E peptides |
WO2010088502A2 (fr) * | 2009-01-30 | 2010-08-05 | The Regents Of The University Of California | Signalisation du facteur de croissance analogue à l'insuline et intégrine |
MA33279B1 (fr) | 2009-04-27 | 2012-05-02 | Novartis Ag | Compositions et procédés pour l'augmentation de la croissance des muscles |
JP5571186B2 (ja) * | 2009-07-22 | 2014-08-13 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | 59位にアミノ酸置換を有するインスリン様増殖因子−1(igf−1)の類似体 |
DK2498796T3 (en) * | 2009-11-09 | 2018-03-05 | Aal Scient Inc | HEART DISEASE TREATMENT |
JP2011160696A (ja) * | 2010-02-08 | 2011-08-25 | Novartis Ag | 修飾ヒトigf−1/eペプチドに対する抗体 |
US8637452B2 (en) | 2011-02-23 | 2014-01-28 | Massachusetts Institute Of Technology | Water soluble membrane proteins and methods for the preparation and use thereof |
US20140357558A1 (en) * | 2011-06-24 | 2014-12-04 | Cold Spring Harbor Laboratory | Compositions and methods for treatment of spinal muscular atrophy |
US9365651B2 (en) | 2011-07-01 | 2016-06-14 | Novartis Ag | Method for treating metabolic disorders by administration of an anti-ActRIIB antibody |
WO2014012025A2 (fr) * | 2012-07-13 | 2014-01-16 | The Trustees Of The University Of Pennsylvania | Protéines igf-1 et leurs utilisations thérapeutiques |
SI2935320T1 (sl) * | 2012-12-18 | 2019-12-31 | Novartis Ag | Stabilizirani polipeptidi inzulinu podobnega rastnega faktorja |
JP6392245B2 (ja) * | 2012-12-18 | 2018-09-19 | ノバルティス アーゲー | 遺伝子改変哺乳動物細胞における治療用タンパク質の産生 |
CN105960414A (zh) | 2013-08-14 | 2016-09-21 | 诺华股份有限公司 | 治疗散发性包涵体肌炎的方法 |
EP3052123A1 (fr) | 2013-10-02 | 2016-08-10 | Novartis Ag | Mimétique du facteur de croissance semblable à l'insuline destiné à être utilisé en thérapie |
UY35874A (es) * | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
KR102313381B1 (ko) * | 2013-12-19 | 2021-10-14 | 퓨어테인 바이오사이언스, 엘엘씨. | 동물을 치료하기 위한 방법 |
JP2017510622A (ja) | 2014-01-27 | 2017-04-13 | ノバルティス アーゲー | 筋萎縮を予測するバイオマーカー、方法および使用 |
US10373702B2 (en) | 2014-03-27 | 2019-08-06 | Massachusetts Institute Of Technology | Water-soluble trans-membrane proteins and methods for the preparation and use thereof |
WO2015149085A2 (fr) * | 2014-03-27 | 2015-10-01 | Massachusetts Institute Of Technology | Protéines membranaires hydrosolubles et leurs procédés de préparation et d'utilisation |
TW201622746A (zh) | 2014-04-24 | 2016-07-01 | 諾華公司 | 改善或加速髖部骨折術後身體復原之方法 |
CN107405387A (zh) * | 2015-02-04 | 2017-11-28 | 普雷坦生物科技有限责任公司 | 用于增加后代的性能特性的方法 |
KR101669140B1 (ko) * | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
US11534466B2 (en) | 2016-03-09 | 2022-12-27 | Aal Scientifics, Inc. | Pancreatic stem cells and uses thereof |
WO2018175460A1 (fr) | 2017-03-24 | 2018-09-27 | Novartis Ag | Procédé pour la prévention et le traitement de maladies cardiaques |
JP6691503B2 (ja) * | 2017-04-13 | 2020-04-28 | 任天堂株式会社 | ゲームプログラム、ゲーム処理制御方法、およびゲーム装置 |
JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
WO2023145961A1 (fr) * | 2022-01-31 | 2023-08-03 | 国立大学法人信州大学 | Cellules exprimant un récepteur antigénique chimérique de forme pré-pro-précurseur ciblant l'igf1r |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
WO1987001038A1 (fr) | 1985-08-22 | 1987-02-26 | Commonwealth Scientific And Industrial Research Or | Analogues peptidiques du facteur de croissance 1 similaire a l'insuline chez les mammiferes |
DE3852636T2 (de) | 1987-12-24 | 1995-05-04 | Gropep Pty Ltd | Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2). |
GB8819826D0 (en) * | 1988-08-20 | 1988-09-21 | Kabivitrum Ab | Glycosylated igf-1 |
EP0639981A4 (fr) * | 1992-05-08 | 1995-06-28 | Univ Jefferson | Analogues du facteur igf-1. |
WO1995013290A1 (fr) | 1993-11-12 | 1995-05-18 | North Shore University Hospital Research Corporation | Methode pour traiter la dystrophie musculaire |
AU2601895A (en) | 1994-05-24 | 1995-12-18 | Amgen Boulder Inc. | Modified insulin-like growth factors |
GB9605124D0 (en) | 1996-03-11 | 1996-05-08 | Royal Free Hosp School Med | Method of treating muscular disorders |
US7118752B2 (en) * | 1998-07-22 | 2006-10-10 | University Of Connecticut | Compositions and methods for inhibiting the proliferation and invasiveness of malignant cells comprising E-domain peptides of IGF-I |
DK1141014T3 (da) * | 1999-01-06 | 2005-04-11 | Genentech Inc | Insulinlignende vækstfaktor (IGF) i mutantvariant |
GB9926968D0 (en) | 1999-11-15 | 2000-01-12 | Univ London | Treatment of neurological disorders |
GB0011278D0 (en) | 2000-05-10 | 2000-06-28 | Univ London | Repair of nerve damage |
IL158419A0 (en) * | 2001-04-19 | 2004-05-12 | Scripps Research Inst | Methods and composition for the production of orthoganal trna-aminoacyl trna synthetase pairs |
SE0104140D0 (sv) * | 2001-12-07 | 2001-12-07 | Astrazeneca Ab | Novel Compounds |
GB0202906D0 (en) | 2002-02-07 | 2002-03-27 | Univ London | Prevention of myocardial damage |
EP2322201A3 (fr) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Les compositions et les methodes pour le traitement de maladies liées immunisées |
US7355018B2 (en) * | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
GB0426154D0 (en) * | 2004-11-29 | 2004-12-29 | European Molecular Biology Lab Embl | IGF-1 novel peptides |
EP1674113A1 (fr) * | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugués de l'IGF-1 et du poly(éthylène glycol) |
AU2006203882B2 (en) * | 2005-01-07 | 2011-05-12 | Regeneron Pharmaceuticals, Inc. | IGF-1 fusion polypeptides and therapeutic uses thereof |
WO2006097682A1 (fr) * | 2005-03-18 | 2006-09-21 | Ucl Business Plc | Peptides du facteur de mecano-croissance et leur utilisation |
KR20080021588A (ko) | 2005-03-18 | 2008-03-07 | 유씨엘 비즈니스 피엘씨 | 메카노 성장 인자 펩티드 및 이들의 용도 |
US20090271875A1 (en) | 2005-03-31 | 2009-10-29 | Pioneer Corporation | Upgrade Module, Application Program, Server, and Upgrade Module Distribution System |
BRPI0712052A2 (pt) | 2006-06-09 | 2012-01-10 | Novartis Ag | polipeptìdeos de fator de crescimento tipo insulina estabilizados |
-
2007
- 2007-06-06 BR BRPI0712052-4A patent/BRPI0712052A2/pt not_active Application Discontinuation
- 2007-06-06 ES ES07798148.8T patent/ES2529261T3/es active Active
- 2007-06-06 MY MYPI20084827A patent/MY147856A/en unknown
- 2007-06-06 AU AU2007255419A patent/AU2007255419A1/en not_active Abandoned
- 2007-06-06 MX MX2008015726A patent/MX2008015726A/es active IP Right Grant
- 2007-06-06 UA UAA200814196A patent/UA97953C2/uk unknown
- 2007-06-06 WO PCT/EP2007/055608 patent/WO2007141309A2/fr active Application Filing
- 2007-06-06 JO JO2007215A patent/JO2968B1/en active
- 2007-06-06 NZ NZ572708A patent/NZ572708A/en not_active IP Right Cessation
- 2007-06-06 EP EP07798148.8A patent/EP2032155B1/fr active Active
- 2007-06-06 US US12/304,068 patent/US8343918B2/en not_active Expired - Fee Related
- 2007-06-06 JP JP2009513697A patent/JP2009539805A/ja active Pending
- 2007-06-06 DK DK07798148.8T patent/DK2032155T3/en active
- 2007-06-06 PT PT77981488T patent/PT2032155E/pt unknown
- 2007-06-06 WO PCT/US2007/070468 patent/WO2007146689A2/fr active Application Filing
- 2007-06-06 AR ARP070102431A patent/AR061242A1/es unknown
- 2007-06-06 CL CL200701614A patent/CL2007001614A1/es unknown
- 2007-06-06 TW TW096120340A patent/TWI427084B/zh not_active IP Right Cessation
- 2007-06-06 MX MX2008015657A patent/MX2008015657A/es not_active Application Discontinuation
- 2007-06-06 JP JP2009514507A patent/JP5290966B2/ja not_active Expired - Fee Related
- 2007-06-06 KR KR1020087029888A patent/KR101459789B1/ko active IP Right Grant
- 2007-06-06 PE PE2007000699A patent/PE20080715A1/es not_active Application Discontinuation
- 2007-06-06 BR BRPI0712147-4A patent/BRPI0712147A2/pt not_active IP Right Cessation
- 2007-06-06 EP EP07729975A patent/EP2032154A2/fr not_active Withdrawn
- 2007-06-06 US US12/303,623 patent/US20100173839A1/en not_active Abandoned
- 2007-06-06 AU AU2007257936A patent/AU2007257936B2/en not_active Ceased
- 2007-06-06 CA CA2654944A patent/CA2654944C/fr not_active Expired - Fee Related
- 2007-06-06 NZ NZ572548A patent/NZ572548A/en not_active IP Right Cessation
- 2007-06-06 PL PL07798148T patent/PL2032155T3/pl unknown
- 2007-06-06 RU RU2008151511/10A patent/RU2477287C2/ru not_active IP Right Cessation
- 2007-06-06 SI SI200731622T patent/SI2032155T1/sl unknown
- 2007-06-06 CA CA002653781A patent/CA2653781A1/fr not_active Abandoned
-
2008
- 2008-11-06 IL IL195156A patent/IL195156A/en not_active IP Right Cessation
- 2008-11-10 CR CR10432A patent/CR10432A/es unknown
- 2008-12-04 GT GT200800273A patent/GT200800273A/es unknown
- 2008-12-05 TN TNP2008000509A patent/TNSN08509A1/en unknown
- 2008-12-08 MA MA31459A patent/MA30503B1/fr unknown
- 2008-12-09 EC EC2008008949A patent/ECSP088949A/es unknown
- 2008-12-11 NO NO20085184A patent/NO20085184L/no not_active Application Discontinuation
- 2008-12-11 NO NO20085183A patent/NO20085183L/no not_active Application Discontinuation
-
2009
- 2009-01-06 DK DK200900016A patent/DK200900016A/da not_active Application Discontinuation
- 2009-06-17 HK HK09105411.1A patent/HK1126429A1/xx not_active IP Right Cessation
-
2012
- 2012-10-30 US US13/664,055 patent/US8722621B2/en not_active Expired - Fee Related
-
2014
- 2014-01-15 US US14/155,974 patent/US20170066808A9/en not_active Abandoned
-
2015
- 2015-03-13 CY CY20151100260T patent/CY1116117T1/el unknown
- 2015-03-23 HR HRP20150326TT patent/HRP20150326T1/hr unknown
-
2016
- 2016-03-07 CR CR20160115A patent/CR20160115A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL195156A0 (en) | Stabilized insulin-like growth factor polypeptides | |
IL194120A0 (en) | Stabilized polypeptide compositions | |
ZA200809384B (en) | Stabilized insulin-like growth factor polypeptides | |
ZA200810738B (en) | Polypeptide | |
HK1135136A1 (en) | Natriuretic polypeptides | |
ZA200901162B (en) | Programmable buoyant delivery technology | |
IL198778A0 (en) | Antibodies against insulin-like growth factor i receptor and uses thereof | |
GB0821798D0 (en) | Temperturre controlled container | |
IL194397A0 (en) | Antibodies against insulin-like growth factor i receptor and uses thereof | |
GB0721686D0 (en) | Polypeptides | |
EP2017283A4 (fr) | Peptide | |
HK1131789A1 (en) | Improved antimicrobial peptides | |
ZA201000283B (en) | Reinigung pegylierter polypeptide | |
EP2010561A4 (fr) | Peptides antimicrobiens | |
EP2029448A4 (fr) | Appareil de transport | |
ZA200807964B (en) | Stabilized polypeptide compositions | |
EP2015766A4 (fr) | Peptides d'alpha-conotoxine cyclises | |
GB0623539D0 (en) | Polypeptides | |
GB0618748D0 (en) | Peptide | |
GB0605774D0 (en) | Peptide | |
IL203073A0 (en) | Modified growth hormone polypeptides | |
IL197675A0 (en) | Peptides | |
EP2091959A4 (fr) | Composition peptidique améliorée | |
GB0712302D0 (en) | Chrondroitinase polypeptides | |
GB0618082D0 (en) | Growth factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190603 |